The Institute for Clinical and Economic Review has been a thorn in pharma’s side for years, with its reviews often concluding drug launches are priced too high. Now, the pain for pharma could spread.
The Institute for Clinical and Economic Review has been a thorn in pharma’s side for years, with its reviews often concluding drug launches are priced too high. Now, the pain for pharma could spread.